408 related articles for article (PubMed ID: 29747541)
1. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
[TBL] [Abstract][Full Text] [Related]
3. Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.
Liesse K; Harris J; Chan M; Schmidt ML; Chiu B
J Pediatr Hematol Oncol; 2018 Aug; 40(6):417-425. PubMed ID: 29432315
[TBL] [Abstract][Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
Wu V
J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
[TBL] [Abstract][Full Text] [Related]
6. Prevention of cardiotoxicity among survivors of childhood cancer.
Hutchins KK; Siddeek H; Franco VI; Lipshultz SE
Br J Clin Pharmacol; 2017 Mar; 83(3):455-465. PubMed ID: 27591829
[TBL] [Abstract][Full Text] [Related]
7. Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.
Kim H; Kang HJ; Park KD; Koh KN; Im HJ; Seo JJ; Lee JW; Chung NG; Cho B; Kim HK; Lee JM; Hah JO; Lee JA; Lee YH; Park SK; Baek HJ; Kook H; Kim JY; Kim HS; Kim HM; Chueh HW; Park M; Yoon HS; Lee MJ; Choi HS; Ahn HS; Kawano Y; Park JW; Hahn S; Shin HY
Cancer Res Treat; 2019 Jan; 51(1):357-367. PubMed ID: 29764117
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
[TBL] [Abstract][Full Text] [Related]
11. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.
Swain SM; Vici P
J Cancer Res Clin Oncol; 2004 Jan; 130(1):1-7. PubMed ID: 14564513
[TBL] [Abstract][Full Text] [Related]
12. Minimizing cardiac toxicity in children with acute myeloid leukemia.
Narayan HK; Getz KD; Leger KJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
[TBL] [Abstract][Full Text] [Related]
13. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
14. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
de Baat EC; van Dalen EC; Mulder RL; Hudson MM; Ehrhardt MJ; Engels FK; Feijen EAM; Grotenhuis HB; Leerink JM; Kapusta L; Kaspers GJL; Merkx R; Mertens L; Skinner R; Tissing WJE; de Vathaire F; Nathan PC; Kremer LCM; Mavinkurve-Groothuis AMC; Armenian S
Lancet Child Adolesc Health; 2022 Dec; 6(12):885-894. PubMed ID: 36174614
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease in survivors of childhood cancer.
Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2005 Jan; (1):CD003917. PubMed ID: 15674919
[TBL] [Abstract][Full Text] [Related]
17. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2008 Apr; (2):CD003917. PubMed ID: 18425895
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials.
Keshavarzian E; Sadighpour T; Mortazavizadeh SM; Soltani M; Motevalipoor AF; Khamas SS; Moazen M; Kogani M; Amin Hashemipour SM; Hosseinpour H; Valizadeh R
Rev Recent Clin Trials; 2023; 18(2):112-122. PubMed ID: 36803186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
